Gregory Zante
Financieel Directeur/CFO bij VIKING THERAPEUTICS, INC.
Vermogen: 12 M $ op 30-04-2024
Profiel
Gregory S.
Zante is currently the Chief Financial Officer at Viking Therapeutics, Inc. He previously held positions as the Director-Finance & Administration at Calyx Therapeutics, Inc., the Senior Vice President at Matrix Pharmaceutical, Inc., the Senior Staff Accountant at Ernst & Young LLP, the Vice President-Finance & Administration at Sangamo Therapeutics, Inc., and the Chief Financial Officer at Aerami Therapeutics, Inc. Mr. Zante obtained his undergraduate degree from the University of California, Los Angeles.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 03-05-2024 | 174 854 ( 0.16% ) | 12 M $ | 30-04-2024 |
Actieve functies van Gregory Zante
| Bedrijven | Functie | Begin |
|---|---|---|
| VIKING THERAPEUTICS, INC. | Financieel Directeur/CFO | 04-01-2021 |
Eerdere bekende functies van Gregory Zante
| Bedrijven | Functie | Einde |
|---|---|---|
Aerami Therapeutics, Inc.
 Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerami Therapeutics, Inc. develops inhaled insulin products to treat diabetes patients. Its product Dance 501 is designed to produce consistently sized particles of liquid insulin in the form of a smooth mist, allowing the efficient and consistent delivery of insulin into the lungs in a few comfortable breaths. The company was founded by John Stuart Patton in February 9, 2009 and is headquartered in Durham, NC. | Financieel Directeur/CFO | 01-01-2016 |
| SANGAMO THERAPEUTICS, INC. | Hoofd Administratief Officier | 01-06-2013 |
| Calyx Therapeutics, Inc. | Financieel Directeur/CFO | - |
Matrix Pharmaceutical, Inc.
 Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | Corporate Officer/Principal | 01-12-2001 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01-11-1995 |
Opleiding van Gregory Zante
| University of California, Los Angeles | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| VIKING THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
| Calyx Therapeutics, Inc. | |
Matrix Pharmaceutical, Inc.
Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Matrix Pharmaceutical, Inc. is a company that researches and develops pharmaceutical products. The company is based in Fremont, CA. The company was founded in 1985 by Dennis M. Brown. Matrix Pharmaceutical was acquired by Chiron Corp. on February 19, 2002 for $58.63 million. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Aerami Therapeutics, Inc.
Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerami Therapeutics, Inc. develops inhaled insulin products to treat diabetes patients. Its product Dance 501 is designed to produce consistently sized particles of liquid insulin in the form of a smooth mist, allowing the efficient and consistent delivery of insulin into the lungs in a few comfortable breaths. The company was founded by John Stuart Patton in February 9, 2009 and is headquartered in Durham, NC. | Health Technology |
